CPIX

Cumberland Pharmaceuticals Inc.
CAPPED RATING

Cumberland Pharmaceuticals Inc., a specialty pharmaceutical company, focuses on the acquisition, development, and commercialization of prescription products for hospital acute care, gastroenterology, rheumatology, and oncology in the United States and internationally. The company offers Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of chronic and acute constipation; Omeclamox-Pak for the treatment of Helicobacter pylori infection and duodenal ulcer disease; Vaprisol, an injection for treating euvolemic and hypervolemic hyponatremia; and Vibativ, an injection for the treatment of certain serious bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections. It also develops RediTrex injection for the treatment of active rheumatoid, juvenile idiopathic, and severe psoriatic arthritis, as well as disabling psoriasis. In addition, the company is developing ifetroban, a product candidate that is in phase II clinical trial for the treatment of aspirin-exacerbated respiratory disease, systemic sclerosis, and duchenne muscular dystrophy; and has completed phase II clinical trial for the treatment of hepatorenal syndrome and portal hypertension. Further, it develops a clinical program for the use of ifetroban to treat progressive fibrosing interstitial lung diseases; and a product candidate that is in Phase II clinical trial for cholesterol reducing agent to use in the hospital setting. The company was incorporated in 1999 and is headquartered in Nashville, Tennessee.

Cumberland Pharmaceuticals Inc. (CPIX) is rated C (2.5/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Profitability (B+); its weakest is Growth (F).

Quantitative Factor Evaluation • Updated

Overall Rating
2.5 / 5.0
C
Value
C-
Factor Score 1.9 / 5.0
Growth
F
Factor Score 0.6 / 5.0
Profitability
B+
Factor Score 3.8 / 5.0
Momentum
B
Factor Score 3.4 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio 37.9
EV / EBITDA 72.9
Rev Growth YoY -56.3%
Gross Margin 85.0%
Price Return 3M -33.0%
Price Return 12M 220.9%
Catalyst Signal 0.00
Market Cap $79.4M
TTM Revenue $44.3M
Price / Sales 1.8
ROE -14.4%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-11 C- (1.9) F (0.6) B+ (3.8) B (3.4) C+ (2.6) C (2.5)
2026-11-04 C- (2.1) F (0.5) B+ (3.8) B (3.4) C+ (2.7) C (2.5)
2026-10-28 C- (2.0) F (0.5) A- (3.9) B+ (3.8) C+ (2.7) C+ (2.6)
2026-10-21 D+ (1.7) F (0.5) A- (3.9) A (4.2) C+ (2.6) C+ (2.6)
2026-10-14 D+ (1.7) F (0.5) A- (3.9) A- (3.9) C+ (2.6) C+ (2.5)
Page 1 of 4